Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
OmniSeq Board Names Margot Schoenborn to Succeed Mark Gardner as CEO
June 26, 2019 10:00 ET
|
OmniSeq
BUFFALO, N.Y., June 26, 2019 (GLOBE NEWSWIRE) -- OmniSeq, Inc. named Margot P. Schoenborn to succeed Mark Gardner as the chief executive officer of the molecular diagnostics and precision medicine...
OmniSeq and LabCorp Extend Exclusive Distribution Pact and Complete Follow-On Investment Agreement
April 23, 2019 08:00 ET
|
OmniSeq
BUFFALO, N.Y., April 23, 2019 (GLOBE NEWSWIRE) -- OmniSeq®, a CAP-accredited, molecular diagnostics spin-out of Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE: LH), a leading global...
OmniSeq, Inc. to Participate in the NCI-MATCH Clinical Trial
July 31, 2018 16:05 ET
|
OmniSeq
BUFFALO, N.Y., July 31, 2018 (GLOBE NEWSWIRE) -- OmniSeq, Inc.® a leading innovator in molecular science, today announced it is participating as a CLIA-certified/accredited laboratory for the...
OmniSeq and LabCorp Launch OmniSeq Advance℠ Assay
June 01, 2018 16:11 ET
|
OmniSeq
CHICAGO, June 01, 2018 (GLOBE NEWSWIRE) -- ASCO – OmniSeq®, a CAP-accredited, molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE:LH), a leading...
Hitachi High-Tech Participates in OmniSeq Series B and Secures Japanese Distribution Rights
April 12, 2018 09:00 ET
|
OmniSeq
BUFFALO, N.Y., April 12, 2018 (GLOBE NEWSWIRE) -- OmniSeq®, a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, announced today Hitachi High-Technologies Corporation...
OmniSeq Receives CAP Accreditation and Publishes Analytical Validation Paper
November 09, 2017 08:02 ET
|
OmniSeq
BUFFALO, N.Y., Nov. 09, 2017 (GLOBE NEWSWIRE) -- OmniSeq, Inc., a molecular diagnostics subsidiary of Roswell Park Cancer Institute, announced today that it received accreditation by the College of...
OmniSeq and LabCorp Sign Exclusive Distribution Agreement and Series B Funding Commitment
August 21, 2017 08:01 ET
|
OmniSeq
BUFFALO, N.Y., Aug. 21, 2017 (GLOBE NEWSWIRE) -- OmniSeq, Inc., a molecular diagnostics subsidiary of the Roswell Park Cancer Institute, announced today that it has entered into an exclusive...
OmniSeq Launches Immune Report Card
June 14, 2017 08:05 ET
|
OmniSeq
BUFFALO, N.Y., June 14, 2017 (GLOBE NEWSWIRE) -- OmniSeq, an innovation of Roswell Park Cancer Institute, announced today the commercial launch of Immune Report Card SM, the first immune profiling...